Streetbeat News

Products Services

PROK

ProKidney is prioritizing its PROACT 1 trial and discontinuing PROACT 2, which was focused on non-U.S. enrollment. This decision is expected to extend their cash runway to Q1 2027 and reduce expenses by $150-$175 million. The company anticipates FDA approval for rilparencel through an expedited pathway.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:39 am

TECK

Teck Resources (NYSE:TECK) has announced a new business structure to focus on energy transition metals, following the sale of its coal unit. The company will operate through North American and Latin American units, emphasizing copper production. Several executives have been promoted to lead this transition.

Portfolio Pulse from Stjepan Kalinic

September 03, 2024 | 11:39 am

SHYF

The Shyft Group's Builtmore Contract Manufacturing has started production of Isuzu's new NRR-EV in Charlotte, Michigan. This move highlights Builtmore's adaptability in the growing electric vehicle market.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:37 am

SNGX

Soligenix has been granted a European patent for 'Systems and Methods for Producing Synthetic Hypericin', which could enhance its intellectual property portfolio and potentially boost its market position.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:35 am

ELAB

Elevai Skincare has released data from a research study indicating that its Elevai Exosomes can cease crown inflammation, reverse miniaturized hairs, and recover hair from the dormant phase.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:34 am

PRAX

Praxis Precision Medicines announced positive topline results from its Phase 2 study of Relutrigine, showing a 46% reduction in monthly motor seizures in patients with SCN2A and SCN8A developmental and epileptic encephalopathy during the double-blind period.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:32 am

IVVD

Invivyd reports that their product PEMGARDA™ (pemivibart) continues to show neutralizing effects against dominant SARS-CoV-2 variants, including KP.3.1.1 and LB.1. The CDC notes KP.3.1.1 is the only major variant increasing nationally. Data has been submitted to the FDA for updates to the PEMGARDA™ Fact Sheet.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:29 am

AZN

AstraZeneca is set to present over 130 abstracts at the IASLC 2024 World Conference on Lung Cancer and the ESMO Congress, showcasing 17 approved and potential new medicines. This includes five Presidential Symposia and 41 oral presentations.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:26 am

CSIQ

Canadian Solar has partnered with SOLARCYCLE to offer recycling services for its solar products, enhancing sustainability in its lifecycle.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:21 am

LI

NIO

TSLA

Tesla's stock is rising in premarket trading due to strong China sales in August, with a 17% increase from July. This performance aligns with domestic rivals like BYD, while Nio and Li Auto saw declines. Tesla's zero-interest financing may have contributed to the sales boost.

Portfolio Pulse from Shanthi Rexaline

September 03, 2024 | 11:20 am